Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...

Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte’s MPN, GVHD and hematology ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

What if you could generate an entire professional deck in minutes? Enter AI-powered presentation makers. These tools are ...

(Terns or the Company) (Nasdaq: TERN), a clinical stage oncology company, today announced that data from the ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor, ...

Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.

From reference managers to note-taking apps, and presentation tools, the research and writing process is getting a high-tech ...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

Founded in 1998, SGC has earned its reputation as one of the most reliable grading companies in the hobby. Its iconic black ...

AI carries a critical undertone that shapes every institution in the country, highlighting the urgency of addressing this ...

CNAP displays verified caller names from telecom databases, boosting trust and authenticity beyond regular number-based ...